艾多沙班 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "艾多沙班" in Chinese language version.

refsWebsite

Global rank Chinese rank

14web.archive.org

1^st place

8europa.eu

68^th place

209^th place

2nih.gov

4^th place

5^th place

2fda.gov

447^th place

581^st place

1doi.org

2^nd place

23^rd place

1drugs.com

399^th place

208^th place

1daiichi-sankyo.eu

low place

1medscape.com

719^th place

889^th place

daiichi-sankyo.eu

First market approval in Japan for Lixiana (Edoxaban). Daiichi Sankyo Europe GmbH (新闻稿). 22 April 2011. （原始内容存档于6 November 2013）.

doi.org

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting FactorXa. Clinical Pharmacokinetics. June 2016, 55 (6): 641–55. PMC 4875962 . PMID 26620048. doi:10.1007/s40262-015-0342-7.

drugs.com

Edoxaban (Savaysa) Use During Pregnancy. Drugs.com. 17 June 2020 [25 September 2020]. （原始内容存档于2021-05-18）.

europa.eu

ema.europa.eu

Lixiana EPAR. European Medicines Agency (EMA). [23 July 2020]. （原始内容存档于2020-10-24）.
Roteas EPAR. European Medicines Agency (EMA). [25 September 2020]. （原始内容存档于2020-11-25）.
Lixiana EPAR. European Medicines Agency (EMA). [23 July 2020]. （原始内容存档于2020-10-24）.
Lixiana, INN-edoxaban (PDF). [6 November 2019]. （原始内容 (PDF)存档于6 November 2019）.
{Cite web|title=Lixiana, INN-edoxaban|url=https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf%7Caccess-date=6^{[失效連結]} November 2019|archive-url=https://web.archive.org/web/20191106140905/https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf%7Carchive-date=6 November 2019}}
Lixiana, INN-edoxaban (PDF). [6 November 2019]. （原始内容 (PDF)存档于6 November 2019）.
Lixiana, INN-edoxaban (PDF). [6 November 2019]. （原始内容 (PDF)存档于6 November 2019）.
Ondexxya. European Medicines Agency. 27 February 2019 [6 November 2019]. （原始内容存档于16 July 2019）.

fda.gov

accessdata.fda.gov

Drug Approval Package: Savaysa (edoxaban tosylate) Tablets NDA #206316. U.S. Food and Drug Administration (FDA). 13 February 2015 [23 July 2020]. （原始内容存档于2022-03-13）.

fda.gov

Ovanesov, Mikhail. Summary basis for regulatory action - ANDEXXA. Food and Drug Administration. 3 August 2017 [6 November 2019]. （原始内容存档于2020-12-06）.

medscape.com

O'Riordan, Michael. FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE Prevention. Medscape. 9 January 2015 [10 January 2015]. （原始内容存档于2017-08-03）.

nih.gov

ncbi.nlm.nih.gov

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting FactorXa. Clinical Pharmacokinetics. June 2016, 55 (6): 641–55. PMC 4875962 . PMID 26620048. doi:10.1007/s40262-015-0342-7.

dailymed.nlm.nih.gov

Savaysa- edoxaban tosylate tablet, film coated. DailyMed. 24 April 2020 [23 July 2020]. （原始内容存档于2020-07-23）.

web.archive.org

Lixiana EPAR. European Medicines Agency (EMA). [23 July 2020]. （原始内容存档于2020-10-24）.
Roteas EPAR. European Medicines Agency (EMA). [25 September 2020]. （原始内容存档于2020-11-25）.
Edoxaban (Savaysa) Use During Pregnancy. Drugs.com. 17 June 2020 [25 September 2020]. （原始内容存档于2021-05-18）.
Savaysa- edoxaban tosylate tablet, film coated. DailyMed. 24 April 2020 [23 July 2020]. （原始内容存档于2020-07-23）.
First market approval in Japan for Lixiana (Edoxaban). Daiichi Sankyo Europe GmbH (新闻稿). 22 April 2011. （原始内容存档于6 November 2013）.
O'Riordan, Michael. FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE Prevention. Medscape. 9 January 2015 [10 January 2015]. （原始内容存档于2017-08-03）.
Drug Approval Package: Savaysa (edoxaban tosylate) Tablets NDA #206316. U.S. Food and Drug Administration (FDA). 13 February 2015 [23 July 2020]. （原始内容存档于2022-03-13）.
Lixiana EPAR. European Medicines Agency (EMA). [23 July 2020]. （原始内容存档于2020-10-24）.
Lixiana, INN-edoxaban (PDF). [6 November 2019]. （原始内容 (PDF)存档于6 November 2019）.
{Cite web|title=Lixiana, INN-edoxaban|url=https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf%7Caccess-date=6^{[失效連結]} November 2019|archive-url=https://web.archive.org/web/20191106140905/https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf%7Carchive-date=6 November 2019}}
Lixiana, INN-edoxaban (PDF). [6 November 2019]. （原始内容 (PDF)存档于6 November 2019）.
Lixiana, INN-edoxaban (PDF). [6 November 2019]. （原始内容 (PDF)存档于6 November 2019）.
Ovanesov, Mikhail. Summary basis for regulatory action - ANDEXXA. Food and Drug Administration. 3 August 2017 [6 November 2019]. （原始内容存档于2020-12-06）.
Ondexxya. European Medicines Agency. 27 February 2019 [6 November 2019]. （原始内容存档于16 July 2019）.